Today, Brokerages Set NCI Building Systems Inc. (NCS) Target Price at $16.90

Today, Brokerages Set NCI Building Systems Inc. (NCS) Target Price at $16.90

NCI Building Systems Inc. (NYSE:NCS) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the company. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $16.90.

NCS has been the topic of several analyst reports. TheStreet raised shares of NCI Building Systems from a “hold” rating to a “buy” rating in a research report on Tuesday, August 30th. Zacks Investment Research raised shares of NCI Building Systems from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, August 25th. Citigroup Inc. reissued a “neutral” rating and set a $16.50 target price on shares of NCI Building Systems in a research report on Wednesday, October 12th. Finally, DA Davidson set a $17.00 target price on shares of NCI Building Systems and gave the stock a “hold” rating in a research report on Wednesday, August 31st.

In other news, Director George L. Ball bought 4,500 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The shares were acquired at an average cost of $15.15 per share, with a total value of $68,175.00. Following the completion of the transaction, the director now directly owns 34,999 shares in the company, valued at $530,234.85. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Norman C. Chambers sold 171,223 shares of NCI Building Systems stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $16.67, for a total value of $2,854,287.41. Following the sale, the chief executive officer now directly owns 743,088 shares in the company, valued at $12,387,276.96. The disclosure for this sale can be found here. 4.49% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Catalyst Capital Advisors LLC purchased a new stake in NCI Building Systems during the third quarter worth $117,000. Acadian Asset Management LLC purchased a new stake in NCI Building Systems during the second quarter worth $130,000. Quantbot Technologies LP purchased a new stake in NCI Building Systems during the third quarter worth $137,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in NCI Building Systems during the second quarter worth $181,000. Finally, Acrospire Investment Management LLC increased its stake in NCI Building Systems by 5.6% in the third quarter. Acrospire Investment Management LLC now owns 13,208 shares of the company’s stock worth $193,000 after buying an additional 700 shares during the period.

Shares of NCI Building Systems (NYSE:NCS) opened at 17.40 on Tuesday. The firm’s 50-day moving average price is $15.15 and its 200 day moving average price is $15.74. NCI Building Systems has a 52 week low of $9.07 and a 52 week high of $17.85. The firm has a market cap of $1.24 billion, a PE ratio of 25.78 and a beta of 1.60.

NCI Building Systems (NYSE:NCS) last posted its earnings results on Tuesday, August 30th. The company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The firm had revenue of $462.40 million for the quarter, compared to the consensus estimate of $450.46 million. NCI Building Systems had a net margin of 3.00% and a return on equity of 20.05%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.15 earnings per share. Equities analysts anticipate that NCI Building Systems will post $0.75 EPS for the current year.

Related posts

Leave a Comment